Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1851 3
1903 2
1906 1
1908 1
1910 2
1912 1
1915 2
1921 1
1922 1
1924 1
1925 1
1931 1
1940 1
1943 1
1944 1
1946 1
1947 2
1948 2
1949 1
1950 5
1951 1
1952 4
1953 6
1954 3
1955 2
1957 4
1958 2
1959 2
1961 3
1962 2
1963 4
1964 1
1965 2
1966 2
1967 3
1968 5
1969 4
1970 3
1971 7
1972 4
1973 1
1974 2
1975 6
1976 2
1977 6
1978 4
1979 6
1980 6
1981 6
1982 8
1983 3
1984 2
1985 3
1986 4
1987 5
1988 8
1989 5
1990 2
1991 2
1992 6
1993 10
1994 4
1995 7
1996 11
1997 8
1998 14
1999 11
2000 14
2001 17
2002 12
2003 23
2004 18
2005 25
2006 15
2007 22
2008 16
2009 22
2010 15
2011 11
2012 23
2013 15
2014 20
2015 16
2016 14
2017 21
2018 10
2019 11
2020 19
2021 32
2022 28
2023 21
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

647 results

Results by year

Filters applied: . Clear all
Page 1
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB; MEASURE 1 Study Group; MEASURE 2 Study Group. Baeten D, et al. Among authors: richards hb. N Engl J Med. 2015 Dec 24;373(26):2534-48. doi: 10.1056/NEJMoa1505066. N Engl J Med. 2015. PMID: 26699169 Free article. Clinical Trial.
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Gottlieb AB, Deodhar A, Mcinnes IB, Baraliakos X, Reich K, Schreiber S, Bao W, Marfo K, Richards HB, Pricop L, Shete A, Trivedi V, Keefe D, Papavassilis CC, Jagiello P, Papanastasiou P, Mease PJ, Lebwohl M. Gottlieb AB, et al. Among authors: richards hb. Acta Derm Venereol. 2022 Apr 27;102:adv00698. doi: 10.2340/actadv.v102.563. Acta Derm Venereol. 2022. PMID: 35146532 Free PMC article.
Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis.
van der Heijde D, Braun J, Deodhar A, Baraliakos X, Landewé R, Richards HB, Porter B, Readie A. van der Heijde D, et al. Among authors: richards hb. Rheumatology (Oxford). 2019 Mar 1;58(3):388-400. doi: 10.1093/rheumatology/key128. Rheumatology (Oxford). 2019. PMID: 29860356 Free PMC article. Review.
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S; FUTURE 1 Study Group. Mease PJ, et al. Among authors: richards hb. N Engl J Med. 2015 Oct;373(14):1329-39. doi: 10.1056/NEJMoa1412679. N Engl J Med. 2015. PMID: 26422723 Free article. Clinical Trial.
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group. McInnes IB, et al. Among authors: richards h. Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28. Lancet. 2015. PMID: 26135703 Free article. Clinical Trial.
Reply by Authors.
Ní Néill E, Richards HL, Hennessey D, Ryan EM, Fortune DG. Ní Néill E, et al. Among authors: richards hl. J Urol. 2023 Jan;209(1):70. doi: 10.1097/JU.0000000000003032.02. Epub 2023 Jan 1. J Urol. 2023. PMID: 36484443 No abstract available.
Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study.
Deodhar A, Blanco R, Dokoupilová E, Hall S, Kameda H, Kivitz AJ, Poddubnyy D, van de Sande M, Wiksten AS, Porter BO, Richards HB, Haemmerle S, Braun J. Deodhar A, et al. Among authors: richards hb. Arthritis Rheumatol. 2021 Jan;73(1):110-120. doi: 10.1002/art.41477. Epub 2020 Nov 24. Arthritis Rheumatol. 2021. PMID: 32770640 Free PMC article. Clinical Trial.
Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head-to-Head Randomized Phase IIIb Study.
Baraliakos X, Østergaard M, Poddubnyy D, van der Heijde D, Deodhar A, Machado PM, Navarro-Compán V, Hermann KGA, Kishimoto M, Lee EY, Gensler LS, Kiltz U, Eigenmann MF, Pertel P, Readie A, Richards HB, Porter B, Braun J. Baraliakos X, et al. Among authors: richards hb. Arthritis Rheumatol. 2024 Aug;76(8):1278-1287. doi: 10.1002/art.42852. Epub 2024 Apr 30. Arthritis Rheumatol. 2024. PMID: 38556921 Clinical Trial.
Preventing Perioperative Sharps Injuries.
Richards H, Henderson T. Richards H, et al. AORN J. 2022 Aug;116(2):176-182. doi: 10.1002/aorn.13751. AORN J. 2022. PMID: 35880914 No abstract available.
Normal-pressure hydrocephalus.
Czosnyka M, Richards HK, Czosnyka Z, Pickard JD. Czosnyka M, et al. Among authors: richards hk. J Neurosurg. 2004 Dec;101(6):1083-4; author reply 1084. doi: 10.3171/jns.2004.101.6.1083. J Neurosurg. 2004. PMID: 15597776 No abstract available.
647 results